Published in Cancer Res on August 15, 2005
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol (2006) 1.41
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 1.33
Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol (2006) 1.32
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol (2007) 1.31
Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res (2009) 1.24
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther (2006) 1.12
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther (2011) 1.07
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther (2008) 1.05
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther (2009) 1.04
Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther (2014) 1.02
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2005) 1.02
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol (2007) 0.99
Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci Lett (2012) 0.98
Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther (2010) 0.98
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res (2011) 0.96
Efficacy of nonviral gene transfer in the canine brain. J Neurosurg (2007) 0.95
High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J Virol (2008) 0.92
Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicol Appl Pharmacol (2013) 0.90
Current status of gene therapy for brain tumors. Transl Res (2012) 0.90
Overview of current immunotherapeutic strategies for glioma. Immunotherapy (2015) 0.89
Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther (2007) 0.88
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med (2010) 0.88
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res (2012) 0.87
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther (2014) 0.87
Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia (2012) 0.86
Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci U S A (2010) 0.86
Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. Hum Gene Ther Clin Dev (2013) 0.86
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics (2012) 0.85
Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Hum Gene Ther Methods (2012) 0.85
Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J Virol (2012) 0.85
Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery (2012) 0.85
Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells. Mol Ther (2012) 0.84
Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One (2010) 0.84
To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses (2016) 0.83
Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev (2014) 0.83
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res (2014) 0.83
Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery (2007) 0.82
Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther (2014) 0.82
Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system. Future Oncol (2006) 0.81
Gene delivery to the nervous system. Mol Ther (2008) 0.81
Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells. ScientificWorldJournal (2013) 0.80
Cell-based immunotherapy against gliomas: from bench to bedside. Mol Ther (2013) 0.78
Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) (2013) 0.78
Emerging immunotherapies for glioblastoma. Expert Opin Emerg Drugs (2016) 0.77
Improved Adeno-associated Viral Gene Transfer to Murine Glioma. J Genet Syndr Gene Ther (2013) 0.77
Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77
Human gene therapy and imaging in neurological diseases. Eur J Nucl Med Mol Imaging (2005) 0.77
Development of an immunotherapeutic adenovirus targeting hormone-independent prostate cancer. Onco Targets Ther (2013) 0.76
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. J Vis Exp (2015) 0.76
Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. Methods Mol Biol (2016) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Mol Ther (2017) 0.75
Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. Neuro Oncol (2016) 0.75
The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors. Adv Pharmacol (2016) 0.75
Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. Hum Gene Ther Methods (2016) 0.75
Abundance of Flt3 and its ligand in astrocytic tumors. Onco Targets Ther (2013) 0.75
Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res (2017) 0.75
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods (1994) 13.53
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 5.32
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood (2000) 5.06
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 2.94
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 2.67
The first 1000 dendritic cell vaccinees. Cancer Invest (2003) 2.44
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med (1997) 2.39
Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol (2001) 2.38
Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med (1997) 2.37
Dendritic cells as vectors for therapy. Cell (2001) 2.18
Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A (2000) 2.05
Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res (1992) 1.95
Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol (1999) 1.81
Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol (1989) 1.79
Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol (2000) 1.72
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer (2003) 1.63
Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther (2000) 1.57
CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res (2005) 1.44
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci (2003) 1.40
Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther (2000) 1.37
Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther (2003) 1.33
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer (2000) 1.32
Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Ther (1994) 1.29
Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst (1994) 1.27
Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii. J Immunol (2000) 1.26
Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods (1996) 1.19
Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. J Gen Virol (1997) 1.19
A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther (1998) 1.13
Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther (2005) 1.12
Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother (2003) 1.11
Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice. J Immunol (2004) 1.09
Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw (2002) 1.08
Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity. Crit Rev Immunol (2002) 1.05
Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther (2003) 1.04
Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother (2002) 1.03
Incidence studies of primary and secondary intracranial tumors: a systematic review of their methodology and results. J Neurooncol (1998) 1.02
Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK. Gene Ther (2000) 1.01
Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol (2001) 1.00
Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol (2003) 1.00
A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother (2003) 0.99
Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol (1999) 0.98
Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther (2002) 0.97
Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med (1999) 0.96
Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res (2001) 0.95
Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Front Biosci (2003) 0.94
Ultrastructural and immunohistological evidence for dendritic-like cells within human choroid plexus epithelium. Neuroreport (1997) 0.92
Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther (2000) 0.92
In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther (2000) 0.91
Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther (1996) 0.90
Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: a rodent model of IL-4-induced hepatitis. J Immunol (2001) 0.88
Incidence of brain tumours in two English counties: a population based study. J Neurol Neurosurg Psychiatry (2000) 0.84
Clinical application of dendritic cells in cancer vaccination therapy. APMIS (2003) 0.83
After initial setback, IL-12 regaining popularity. J Natl Cancer Inst (1996) 0.82
Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther (2002) 0.82
Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand. Exp Gerontol (2004) 0.82
CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother (2004) 0.81
There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum. Brain Res Dev Brain Res (1998) 0.80
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 9.09
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science (2011) 8.53
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med (2007) 7.87
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57
Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 5.47
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 5.00
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature (2007) 4.88
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43
MHC class II-dependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol (2009) 4.28
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med (2009) 4.07
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science (2008) 3.97
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med (2011) 3.88
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med (2006) 3.43
Microglia promote the death of developing Purkinje cells. Neuron (2004) 3.42
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol (2009) 3.41
Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med (2002) 3.27
Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood (2010) 3.26
Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 3.17
The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab (2010) 3.11
Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol (2007) 3.06
Blood monocyte subsets differentially give rise to CD103+ and CD103- pulmonary dendritic cell populations. J Immunol (2008) 3.04
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol (2007) 2.84
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol (2006) 2.70
Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med (2004) 2.68
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity (2006) 2.62
Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity (2013) 2.61
Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol (2011) 2.57
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood (2009) 2.55
A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med (2011) 2.54
Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A (2012) 2.54
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology (2010) 2.53
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med (2006) 2.51
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology (2010) 2.48
Disease-specific molecular events in cortical multiple sclerosis lesions. Brain (2013) 2.48
Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol (2006) 2.48
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation (2011) 2.45
Remyelination is extensive in a subset of multiple sclerosis patients. Brain (2006) 2.43
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res (2011) 2.42
Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature (2012) 2.41
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. J Immunol (2002) 2.40
Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest (2011) 2.37
CCR2 promotes hepatic fibrosis in mice. Hepatology (2009) 2.35
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci (2004) 2.35
Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med (2012) 2.33
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest (2006) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31